Curable. Inc.

Equities

A086460

KR7086460003

Biotechnology & Medical Research

End-of-day quote Korea S.E. Other stock markets 23:00:00 23/05/2024 BST			5-day change	1st Jan Change
4,785 ^KRW	-0.10%		+9.62%	-27.17%

2023	Curable. Inc. agreed to acquire 8.5% stake in Pharma Biotech Korea Co., Ltd from Pharma Biotech Korea for KRW 8.5 billion.	CI
2023	Curable. Inc. announced that it has received KRW 5.0009986 billion in funding from GW Vitek CO.,LTD.	CI

SNP Genetics Inc. acquired an additional 0.05% stake in Enzychem Lifesciences Corporation.

November 06, 2014 at 04:00 am

SNP Genetics Inc. acquired an additional 0.05% stake in Enzychem Lifesciences Corporation on November 5, 2014. SNP Genetics Inc. acquired 0.003 million shares and increased its holding to 0.069 million shares in Enzychem Lifesciences Corporation.

SNP Genetics Inc. completed the acquisition of an additional 0.05% stake in Enzychem Lifesciences Corporation on November 5, 2014.

Latest news about Curable. Inc.

Curable. Inc. agreed to acquire 8.5% stake in Pharma Biotech Korea Co., Ltd from Pharma Biotech Korea for KRW 8.5 billion.	19/01/23	CI
Curable. Inc. announced that it has received KRW 5.0009986 billion in funding from GW Vitek CO.,LTD.	18/01/23	CI
SNP Genetics Inc. announced that it has received KRW 10 billion in funding from Kalis BNT Co., Ltd.	22/05/22	CI
Curable. Inc. announced that it expects to receive KRW 9.999995 billion in funding from GW Vitek CO.,LTD.	18/05/22	CI
SNP Genetics Inc. announced that it expects to receive KRW 10 billion in funding from Kalis BNT Co., Ltd.	15/05/22	CI
An unknown buyer agreed to acquire 16.82% of stake in SNP Genetics Inc. from Jo, Jin-hwan and others for KRW 3.7 billion.	18/04/22	CI
SNP Genetics Inc. announced that it has received KRW 2.49999872 billion in funding	13/04/22	CI
SNP Genetics Inc. announced that it expects to receive KRW 2 billion in funding	05/04/22	CI
SNP Genetics Inc. announced that it expects to receive KRW 2.49999872 billion in funding	05/04/22	CI
GW Vitek CO.,LTD. agreed to acquire a 40.7% stake in SNP Genetics Inc. from Hyoung-doo Shin and Myung-cheol Kim for KRW 9.4 billion.	20/02/22	CI
Tranche Update on SNP Genetics Inc.'s Equity Buyback Plan announced on November 2, 2020.	05/02/21	CI
SNP Genetics Inc.'s Equity Buyback announced on November 2, 2020, has expired with 110,000 shares, for KRW 104.72 million.	01/02/21	CI
SNP Genetics Inc. announces an Equity Buyback for 277,777 shares, for KRW 1,000 million.	02/11/20	CI
SNP Genetics Inc. authorizes a Buyback Plan.	01/11/20	CI
SNP Genetics Inc. cancelled the acquisition of an additional 0.99% stake in Enzychem Lifesciences Corporation from Capitalworks Investment Co.,Ltd.	06/11/15	CI
SNP Genetics Inc. acquired an additional 0.82% stake in Enzychem Lifesciences Corporation.	06/11/14	CI
SNP Genetics Inc. acquired an additional 0.02% stake in Enzychem Lifesciences Corporation.	06/11/14	CI
SNP Genetics Inc. agreed to acquire an additional 0.99% stake in Enzychem Lifesciences Corporation from Capitalworks Investment Co.,Ltd. for KRW 780 million.	06/11/14	CI
SNP Genetics Inc. acquired an additional 0.05% stake in Enzychem Lifesciences Corporation.	06/11/14	CI
SNP Genetics Inc. acquired an additional 0.025% stake in Enzychem Lifesciences Corporation.	06/11/14	CI
Cheol-Hoon Oh, Myoung-Ho Kim, Hyoung-Doo Shin, SNP Genetics Inc., Mi-Soon Kim, S&F Venture Capital Co., Ltd., Sang-Ho Jung and Nano SM Co., Ltd. acquired 3.4% stake in Enzychem Lifesciences Corporation from Capitalworks Investment Co.,Ltd. for KRW 1.7 billion.	29/08/14	CI
Tranche Update on SNP Genetics Inc.'s Equity Buyback Plan announced on November 15, 2013.	17/02/14	CI
SNP Genetics Inc.’s Equity Buyback announced on November 15, 2013 has expired with 75,000 shares for KRW 210 million.	15/02/14	CI
SNP Genetics Inc. authorizes a Buyback Plan.	14/11/13	CI
SNP Genetics Inc. announces an Equity Buyback for 141,700 shares.	14/11/13	CI

Chart Curable. Inc.

Duration

Period

More charts

Company Profile

Curable Inc, SNP Genetics Inc, is a Korea-based company mainly engaged in the analysis of genomes. The company is involved in the research and development of disease-related single nucleotide polymorphism (SNP) contents using SNP. These diseases include asthma, diabetes, osteoporosis, alcoholism, tuberculosis, cancer, multiple sclerosis, obesity, mental illness, metabolic disease, lupus disease. The Company is involved in the production and sale of Kobreed kits, as well as the provision of SNP Care. The Kobreed kits are medicine for discriminating Korean beef and imported meat. SNP Care is a gene analysis service. In addition, the Company is engaged in leasing of the places of business. The major customers include government agencies such as the Disease Control Headquarters and the Food and Drug Administration.

Sector

Biotechnology & Medical Research

More about the company

Sector Bio Diagnostics & Testing

	1st Jan change	Capi.
CURABLE. INC.	-27.17%	10.31M
EXACT SCIENCES CORPORATION	-32.63%	9.98B
IOVANCE BIOTHERAPEUTICS, INC.	+23.12%	2.87B
BGI GENOMICS CO., LTD.	-18.33%	2.07B
VERACYTE, INC.	-24.39%	1.59B
MARAVAI LIFESCIENCES HOLDINGS, INC.	+65.65%	1.43B
CAREDX, INC	+32.83%	824M
SEEGENE, INC.	-6.77%	733M
ADAPTIVE BIOTECHNOLOGIES CORPORATION	-29.80%	508M
CURIOX BIOSYSTEMS CO., LTD	+0.40%	296M

Bio Diagnostics & Testing